文献速递真菌感染细菌感染、耐药与抗菌药物

血液病患者侵袭性曲霉病死亡率25年改善:能否持续或面临威胁?

25 years of improvement in mortality in invasive aspergillosis in haematology patients: will it be sustained or is it under threat?
PubMed 文献 · J Antimicrob Chemother · 2026-01-01

综述指出,过去数十年侵袭性曲霉病(IA)粗死亡率持续下降,主要归因于常规采用抗霉菌活性药物尤其是唑类。新诊断工具和综合管理也推动更早靶向治疗,但难以量化其独立贡献。唑类耐药、曲霉与毛霉共存及药物相互作用正威胁这一改善,促使新型抗真菌药研发。

要点

  • IA粗死亡率持续下降,主要归因于常规使用抗霉菌活性唑类药物。
  • 患者群体趋向高龄、高共病、更严重基础病,可能掩盖管理进步的独立影响。
  • 唑类耐药、曲霉与毛霉共存及药物相互作用正威胁死亡率改善的持续性。

核心结论

  • 过去数十年IA粗死亡率持续下降,但近期唑类耐药等因素可能威胁这一改善的可持续性。

研究设计与样本

  • 本文为综述,总结随机对照临床试验和大型人群调查中IA死亡率变化趋势及相关管理进展。

主要发现

  • 随机对照临床试验和大型人群调查均显示IA粗死亡率持续下降。
  • 常规采用抗霉菌活性药物尤其是唑类是死亡率下降的最主要单一因素。
  • 患者群体向更高龄、更脆弱、基础病更严重方向演变,可能掩盖诊断和支持治疗进步的独立影响。

临床怎么用

  • 临床应重视常规采用抗霉菌活性唑类药物以降低IA死亡率。
  • 需关注唑类耐药、曲霉与毛霉共存及药物相互作用对疗效的威胁。

局限性

  • 难以区分IA死亡率改善中IA管理进步与基础病管理进步的各自贡献。
  • 共识定义、诊断工具改进和早期靶向策略的影响难以基于现有数据量化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Invasive aspergillosis (IA) crude mortality has shown a sustained reduction over the past decades, demonstrated in randomized controlled clinical trials of new antifungal agents and across large population surveys. New diagnostic tools and integrated management approaches have driven faster, more targeted initiation of appropriate antifungal therapy. In parallel, improvements in the identification of periods at highest risk for IA and in practices for management of the underlying disease processes predisposing to immunosuppression, including immunomodulatory therapies, have progressed. Given the highly complex and interconnected relationship between the underlying disease and its treatment and the predisposition to IA that the underlying disease creates, it is difficult to separate out which mortality improvements could be attributable to improved management of IA and which to better management of the underlying disease. The reductions in IA mortality have been sustained despite increases in the number of older, more vulnerable patients with more severe underlying disease undergoing treatment for acute haematological disorders and haematopoietic cell transplantation. This gradual and subtle move to a higher risk, more co-morbid patient population may have obscured any impact from the management developments other than antifungal therapy over this period, including better fungal diagnosis and supportive care. The overwhelming single factor contributing to a reduction in IA mortality over the past years appears to have been the routine adoption of mould-active antifungals, azoles in particular. Any impact of consensus definitions used to classify disease, improvements in diagnostic tools and earlier targeted strategies, remains difficult to measure based on available data. However, recently, the use of mould-active azoles has become threatened by the emergence of azole resistance in Aspergillus fumigatus, the frequent co-occurrence of Aspergillus species and Mucorales species, and difficult to handle drug-drug interactions, thereby fuelling an ongoing search for novel antifungal agents.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Maertens JA, Vanbiervliet Y, Mercier T, et al. 25 years of improvement in mortality in invasive aspergillosis in haematology patients: will it be sustained or is it under threat? J Antimicrob Chemother. 2026. PMID: 41790511. doi:10.1093/jac/dkag077

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。